Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Achieving and maintaining a high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012 study, in 458 patients aged ≤65 years with NDMM, is evaluating bortezomib (subcutaneous) + lenalidomide + dexamethasone (VRD) for 6 cycles fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Rosiñol, Laura, Oriol, Albert, Rios, Rafael, Sureda, Anna, Blanchard, María Jesús, Hernández, Miguel Teodoro, Martínez-Martínez, Rafael, Moraleda, Jose M., Jarque, Isidro, Bargay, Juan, Gironella, Mercedes, de Arriba, Felipe, Palomera, Luis, González-Montes, Yolanda, Martí, Josep M., Krsnik, Isabel, Arguiñano, Jose M., González, Maria Esther, González, Ana Pilar, Casado, Luis Felipe, López-Anglada, Lucia, Paiva, Bruno, Mateos, Maria-Victoria, San Miguel, Jesus F., Lahuerta, Juan-José, Bladé, Joan
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2019
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6888142/
https://ncbi.nlm.nih.gov/pubmed/31484647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019000241
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados